Skip to content

AN OPEN LABEL SINGLE ARM CLINICAL TRIAL TO ASSESS THE EFFECTS OF SARSAPARILLA 3X IN URINARY TRACT INFECTION IN ADULTS OF 18-45years

AN OPEN LABEL STUDY TO ASSESS THE EFFECTIVENESS OF SARSAPARILLA OFFICINALIS 3X IN URINARY TRACT INFECTION BY ESTIMATING PUS CELLS - nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084589
Enrollment
53
Registered
2025-04-11
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N300- Acute cystitis

Interventions

Intervention1: Sarsaparilla Officinalis 3X: Sarsaparilla Officinalis 3X potency twice a day, repetition and dose will be based on questionnaire scoring Control Intervention1: Not applicable: Not appli

Sponsors

Metropolitan Homoepathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed cases of urinary tract infection and/or with clinical features of UTI of age group 18- 45years,in females irrespective of their socio-economic status. 2. Patients having pus cells in urine greater than 10/HPF. 3. Subjects agree to comply with the protocol.

Exclusion criteria

Exclusion criteria: 1. Patients associated with conditions like myocardial infarction, renal failure, hepatic failure, malignancies and metabolic disorders like diabetes mellitus with clinical evidences and complicated cases of UTI such as pyelonephritis, urethral stricture, sepsis with clinical evidences. 2. Patients are unconscious, ambulatory, too sick for consultation, differently abled, terminally or critically ill patients, mentally incompetent people, unstable mental or psychiatric illness. 3. Already taking treatment for any other chronic diseases. 4. Patient who has been dealing with urinary symptoms with several modern medication. 5. Pregnant and lactating mothers. 6. Catheter induced UTI. 7. Self-reported immune-compromised state.

Design outcomes

Primary

MeasureTime frame
Pre post changes in pus cell count in routine examination of urineTimepoint: Pre post changes in pus cell count in routine examination of urine, 2 weeks from baseline

Secondary

MeasureTime frame
UTI Symptom Assessment questionnaire, TLC in CBC reportTimepoint: 2 weeks

Countries

India

Contacts

Public ContactDoctor Chandranath Das

Metropolitan Homoeopathic Medical College and Hospital

ehtesham.khan.nih@gmail.com8100099839

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026